Clinical trial Recruiting at 1 site Interventional Ages 21 and up

Using CT to Measure Heart Fibrosis in Atrial Fibrillation Patients Before Ablation

Official title: 320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.

Run by Johns Hopkins University · NCT06308094 · Data updated 2026-11-12

This study tests if measuring heart tissue changes with a CT scan can help predict how well people with Atrial Fibrillation will do after a heart procedure.

More Atrial Fibrillation trials

Quick facts

Study typeInterventional
Ages21 Years and up
SexAll
Enrollment100 (estimated)
SponsorJohns Hopkins University
Academic / other
Locations1 site (Baltimore, Maryland)
StatusRecruiting
StartedApril 10, 2025
Main results expectedDecember 1, 2026
Study endsDecember 1, 2026
Registry record updatedApril 13, 2026
Trial IDNCT06308094 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 21 and older with symptomatic paroxysmal or persistent atrial fibrillation who are suitable for ablation.

Probably not a fit

Patients with known allergies to iodinated contrast media or those with severe renal impairment may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the link between myocardial fibrosis and outcomes in patients with Atrial Fibrillation (AF) undergoing catheter ablation. It utilizes Cardiac CT to measure left ventricular extracellular volume (ECV) as a potential indicator of fibrosis. The research aims to determine if higher ECV levels are associated with increased risks of AF recurrence, hospitalization, and poor recovery of cardiac function. By establishing this relationship, the study could influence treatment strategies for AF based on ECV measurements.

Why it matters

Potential benefit: If successful, this study could help identify patients at higher risk for poor outcomes after AF ablation, leading to more personalized treatment approaches.

How similar studies have gone: While the use of ECV as a prognostic tool in AF is relatively novel, similar studies have shown promise in other cardiac conditions.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients must be at least 21 years old at the time of enrollment.
* Patients must be able to give informed consent.
* Patients with symptomatic paroxysmal/persistent atrial fibrillation (AF).
* Eligible patients must be determined to be suitable candidates for ablation to treat AF by their cardiologist and/or electrophysiologists regardless of this protocol.
* Patients are scheduled to have a pre-procedure cardiac CT upon the discretion of their electrophysiologists

Exclusion Criteria:

* Known allergy to iodinated contrast media.
* Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula).
* Patients with a positive urine or serum pregnancy test will be excluded from this study.
* Patients with heart transplantation.
* Patients with polymorphic ventricular tachycardia (VT) or presenting in electrical storm.
* Presence of any other history or condition that the investigator feels would be problematic.
* Patient with iodinated contrast administration for other reason 24 hours prior to investigational CT.
* Patients who have a heart pacemaker, metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain, mechanical heart valves and prosthetics that contain metal.
* Patients with severe claustrophobia.

Where it's running

  • Johns Hopkins Hospital
    Baltimore, Maryland, United States
    Recruiting

Study contacts

  • Principal investigator: Konstantinos Aronis, MD, PhD — Johns Hopkins School of Medicine
  • Study coordinator: Konstantinos Aronis, MD PHD
  • Email: karonis1@jhmi.edu
  • Phone: 2017169226

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.